Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Aug 01, 2023 12:29pm
101 Views
Post# 35567080

RE:RE:RE:RE:Mr Mugsy & three type of self investors

RE:RE:RE:RE:Mr Mugsy & three type of self investors We could have easily already hit bottom. TIme will tell. 

Volume has dropped noticeably in the last couple of months, which could be a function of an increasingly smaller float. Knight keeps buying back shares and I have also noticed someone from CIBC buying a lot as well. 

Also, if you look at the operations, last quarter flipped to positive territory. It's possible that with the platform created and Exelon and other drugs coming fully online that EBIT could be positive going forward. We'll see what happens with Q2 as it might be too early to say. 

The funds have been a drag the last two quarters so hopefully we'll have seen those rebound as so many things have since beginning of 23'. I would guess that will also be positive but I haven't looked to deeply into that. 

Then there's potential catalyst of CRA dispute which has also been dragging its feet. It would be nice if management could speak to that on the conf. call.

Lastly, even though they have mentioned BusDev is strong, there hasn't been any deals announced this year. Maybe they have their hands full with current portfolio and waiting for a bigger/better deal? Would be nice to get more color on that instead of another "we're very busy with deal flow and it's strong..."
<< Previous
Bullboard Posts
Next >>